These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 27092785)
1. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Phillips KA; Regan MM; Ribi K; Francis PA; Puglisi F; Bellet M; Spazzapan S; Karlsson P; Budman DR; Zaman K; Abdi EA; Domchek SM; Feng Y; Price KN; Coates AS; Gelber RD; Maruff P; Boyle F; Forbes JF; Ahles T; Fleming GF; Bernhard J Br J Cancer; 2016 Apr; 114(9):956-64. PubMed ID: 27092785 [TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816 [TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. O'Regan RM; Zhang Y; Fleming GF; Francis PA; Kammler R; Viale G; Dell'Orto P; Lang I; Bellet M; Bonnefoi HR; Tondini C; Villa F; Bernardo A; Ciruelos EM; Neven P; Karlsson P; Müller B; Jochum W; Zaman K; Martino S; Geyer CE; Jerzak KJ; Davidson NE; Coleman RE; Ingle JN; van Mackelenbergh MT; Loi S; Colleoni M; Schnabel CA; Treuner K; Regan MM JAMA Oncol; 2024 Oct; 10(10):1379-1389. PubMed ID: 39145953 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM; J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334 [No Abstract] [Full Text] [Related]
5. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ; J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365 [TBL] [Abstract][Full Text] [Related]
6. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM; J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ; Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609 [TBL] [Abstract][Full Text] [Related]
8. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients. Abbas W; Rao RR Indian J Cancer; 2019; 56(4):293-296. PubMed ID: 31607695 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. Francis PA Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. Pagani O; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Goetz MP; Ciruelos EM; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Chini C; Puglisi F; Spazzapan S; Ruhstaller T; Winer EP; Ruepp B; Loi S; Coates AS; Gelber RD; Goldhirsch A; Regan MM; Francis PA; J Clin Oncol; 2023 Mar; 41(7):1376-1382. PubMed ID: 36521078 [No Abstract] [Full Text] [Related]
11. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients]. Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608 [TBL] [Abstract][Full Text] [Related]
12. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Mathew A; Davidson NE Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743 [TBL] [Abstract][Full Text] [Related]
14. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study. Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022 [TBL] [Abstract][Full Text] [Related]
15. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM; N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451 [TBL] [Abstract][Full Text] [Related]
16. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. Tevaarwerk AJ; Wang M; Zhao F; Fetting JH; Cella D; Wagner LI; Martino S; Ingle JN; Sparano JA; Solin LJ; Wood WC; Robert NJ J Clin Oncol; 2014 Dec; 32(35):3948-58. PubMed ID: 25349302 [TBL] [Abstract][Full Text] [Related]
17. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time? Montagna E; Cancello G; Colleoni M Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China. Zhong X; Chen P; He P; Wu Y; Suo J; Zhu K; Yan X; Tian T; Yang Q; Luo T Clin Breast Cancer; 2024 Feb; 24(2):e41-e50. PubMed ID: 37865566 [TBL] [Abstract][Full Text] [Related]
19. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report. Kim HJ; Noh WC; Nam SJ; Park BW; Lee ES; Im SA; Jung YS; Yoon JH; Kang SS; Park KH; Lee SJ; Jeong J; Lee MH; Cho SH; Kim SY; Kim HA; Han SH; Han W; Hur MH; Kim S; Ahn SH Eur J Cancer; 2021 Jul; 151():190-200. PubMed ID: 34010788 [TBL] [Abstract][Full Text] [Related]